Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Buy
64
TRUMY Quote, Financials, Valuation and Earnings
Last price:
$19.18
Seasonality move
:
6.28%
Day range:
$19.37 - $19.45
52-week range:
$14.06 - $21.22
Dividend yield:
0.8%
P/E ratio:
35.82x
P/S ratio:
4.44x
P/B ratio:
3.20x
Volume:
35K
Avg. volume:
181.7K
1-year change:
14.89%
Market cap:
$28.6B
Revenue:
$6.4B
EPS (TTM):
$0.54
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Terumo has -- downside to fair value with a price target of -- per share.
TRUMY vs. S&P 500
-
Over the past 5 trading days, Terumo has underperformed the S&P 500 by -0.03% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Terumo does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Terumo has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Terumo reported revenues of $1.7B.
Earnings Growth
-
Terumo has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Terumo reported earnings per share of $0.16.
Enterprise value:
28.4B
EV / Invested capital:
--
Price / LTM sales:
4.44x
EV / EBIT:
26.42x
EV / Revenue:
4.35x
PEG ratio (5yr expected):
1.48x
EV / Free cash flow:
60.71x
Price / Operating cash flow:
53.60x
Enterprise value / EBITDA:
17.53x
Gross Profit (TTM):
$3.5B
Return On Assets:
6.77%
Net Income Margin (TTM):
12.28%
Return On Equity:
9.13%
Return On Invested Capital:
7.94%
Operating Margin:
17.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $6.1B | $6.3B | $6.5B | $1.6B | $1.7B | |
| Gross Profit | $3.1B | $3.2B | $3.5B | $857.3M | $951.4M | |
| Operating Income | $871.1M | $915.8M | $1.1B | $264.3M | $300.1M | |
| EBITDA | $1.4B | $1.5B | $1.6B | $402.8M | $448.8M | |
| Diluted EPS | $0.44 | $0.47 | $0.54 | $0.14 | $0.16 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.7B | $4.7B | $4.4B | $4.7B | $4.7B | |
| Total Assets | $12.2B | $12.2B | $11.8B | $12B | $12B | |
| Current Liabilities | $1.5B | $1.6B | $1.5B | $2.5B | $1.7B | |
| Total Liabilities | $4.7B | $4B | $3.6B | $3.4B | $3B | |
| Total Equity | $7.5B | $8.1B | $8.2B | $8.6B | $8.9B | |
| Total Debt | $2.5B | $2.2B | $1.8B | $1.6B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.3B | $870.4M | $1B | $339.4M | $396.4M | |
| Cash From Investing | -$698.8M | -$437.8M | -$564.6M | -$140.6M | -$205.2M | |
| Cash From Financing | -$631.4M | -$641M | -$430.2M | -$42M | $35.2M | |
| Free Cash Flow | $600M | $335.9M | $468.2M | $178.4M | $215.3M | |
TRUMY
Sector
Market Cap
$28.6B
$34.9M
Price % of 52-Week High
91.28%
44.35%
Dividend Yield
0.8%
0%
Shareholder Yield
2.63%
-0.82%
1-Year Price Total Return
14.89%
-38.5%
Beta (5-Year)
0.755
0.738
Dividend yield:
0.8%
Annualized payout:
$0.14
Payout ratio:
13.63%
Growth streak:
9 years
Technicals
8-day SMA
Buy
Level
$19.25
200-day SMA
Buy
Level
$18.82
Bollinger Bands (100)
Buy
Level
18.15 - 19.61
Chaikin Money Flow
Sell
Level
-480.4K
20-day SMA
Buy
Level
$18.87
Relative Strength Index (RSI14)
Buy
Level
58.07
ADX Line
Buy
Level
11.42
Williams %R
Neutral
Level
-30.5677
50-day SMA
Buy
Level
$18.48
MACD (12, 26)
Buy
Level
0.23
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
1.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.6701)
Buy
CA Score
(Annual)
Level (1.0744)
Buy
Beneish M-Score
(Annual)
Level (-2.5436)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-2.9537)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2024, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 36% of Terumo’s revenue.
Stock Forecast FAQ
In the current month, TRUMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRUMY average analyst price target in the past 3 months is --.
-
Where Will Terumo Stock Be In 1 Year?
According to analysts, the consensus estimate is that Terumo share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Terumo?
Analysts are divided on their view about Terumo share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Terumo is a Sell and believe this share price will rise from its current level to --.
-
What Is Terumo's Price Target?
The price target for Terumo over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRUMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Terumo is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TRUMY?
You can purchase shares of Terumo via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Terumo shares.
-
What Is The Terumo Share Price Today?
Terumo was last trading at $19.18 per share. This represents the most recent stock quote for Terumo. Yesterday, Terumo closed at $19.37 per share.
-
How To Buy Terumo Stock Online?
In order to purchase Terumo stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
